



NEWS RELEASE

Dr. Andrew MacKenzie Joins Novation's Scientific Advisory Board

FOR IMMEDIATE RELEASE

January 19th, 2016

Burnaby, Canada: Novation Pharmaceuticals Inc., Canada, today announced that Dr. Andrew MacKenzie has joined Novation's Scientific Advisory Board.

Dominique Cheneval, CEO of Novation said today; "We are delighted that Dr. MacKenzie has agreed to join our SAB and is able to provide his scientific and large Pharma expertise to management in Novation. Dr. MacKenzie's background in immunological diseases and vast experience in drug discovery and development will add an invaluable asset to Novation as the Company advances its cytokine inhibitor program. We very much looking forward to working with him as we continue to develop and exploit Novation's *Quest* technology".

About Novation and the *Quest* Technology

Novation is a product-focused company using *Quest*, its breakthrough drug-discovery technology that harnesses a natural cellular control function, messenger RNA (mRNA) modulation, to identify new therapeutics for a broad range of diseases. *Quest* uses cell-based assays to identify small molecules that impact protein expression via mRNA modulation.

The ability to affect mRNA function with small molecular weight compounds opens up a wide range of disease areas to therapeutic intervention including "non-drugable" targets and to diseases currently treated with biologicals. In the cell, mRNA regulation determines which proteins get made, how much is produced, and for how long, and as such, is a highly controlled cellular process. The regulation of mRNA function is exerted through specific motifs present within each individual mRNA. Novation scientists incorporate these motifs for a particular target mRNA into a high-throughput reporter gene assay system (the *Quest* technology) which is then screened to identify small molecules that work through these motifs. A non-biased approach, *Quest* can identify both inhibitory and stimulatory small molecule compounds that modulate the stability of a target mRNA or influence its translatability.

Novation's suite of *Quest* drug-discovery assays span a number of disease areas including targets in oncology, inflammation, cardiometabolic, neurodegeneration, dyslipidemia, and is developing assays in other therapeutic areas poorly served.

This news release contains certain forward looking statements. Actual results may differ materially from the statements made as a result of various factors, including, but not limited to, the inherent risks associated with drug research and development, difficulties or delays in development testing, changes in regulatory affairs, lack of therapeutic efficacy, unacceptable side-effects, the dependence on partners, the inability to raise sufficient finance, the appearance of competitors and other risks generally associated with the biopharmaceutical industry.

For further information contact:

Dominique Cheneval, Ph.D.
CEO and Co-Founder
Novation Pharmaceuticals Inc.
4475 Wayburne Drive, Suite 314
Burnaby, B.C., Canada V5G 4X4
Telephone: 604. 432.7068
Email: dcheneval@novation-pharma.com
Web Site: www.novation-pharma.com